In a J Clin Endocrinol Metab randomized trial, Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. Key reported results included Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to…
Browsing: Endocrinology
In a J Clin Endocrinol Metab randomized trial, Ultrasound alone appears to be an effective diagnostic modality in thyroid nodules, confirming the recommendations of recent guidelines and the British Thyroid Association classification. Key reported results included Of the 982 participants, a final…
In a J Clin Endocrinol Metab randomized trial, The reported efficacy, pharmacokinetic, pharmacodynamic, safety, and immunogenicity data support the biosimilarity of SB16 to DEN. Key reported results included The least-squares mean differences in percent change from baseline in lumbar spine BMD at…
In a J Clin Endocrinol Metab randomized trial, We found no evidence that SGTF was associated with differences in adolescent brain morphology, and no effect of levothyroxine supplementation. Key reported results included There were no significant differences in global brain volumetric measures…
In CHIRACIC, adrenalectomy improved home-blood-pressure normotension with less medication versus conservative management in unilateral mild autonomous cortisol secretion-associated hypertension.
In ACROINNOVA 1, monthly self-injected CAM2029 maintained IGF-1 control in 72.2% of adults with controlled acromegaly versus 37.5% on placebo withdrawal.
In an open-label Graves disease RCT, methotrexate 10 mg weekly added to methimazole increased treatment withdrawal at 18 months, but remains investigational.
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
In early postmenopausal women aged 50 to 60 years, zoledronate at baseline and 5 years reduced 10-year morphometric vertebral fractures from 11.1% to 6.3%.
In the IoN non-inferiority RCT, omitting postoperative radioiodine after total thyroidectomy produced 5-year recurrence-free survival of 97.9% versus 96.3% with ablation in selected low-risk thyroid cancer.